Nicola P Klein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8032141/publications.pdf

Version: 2024-02-01

140	7,021	41	79
papers	citations	h-index	g-index
141	141	141	5871 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	13.9	709
2	Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children. New England Journal of Medicine, 2012, 367, 1012-1019.	13.9	471
3	Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA - Journal of the American Medical Association, 2021, 326, 1390.	3.8	442
4	Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures. Pediatrics, 2010, 126, e1-e8.	1.0	290
5	The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety. Pediatrics, 2011, 127, S45-S53.	1.0	247
6	Risk of Intussusception after Monovalent Rotavirus Vaccination. New England Journal of Medicine, 2014, 370, 513-519.	13.9	201
7	Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine, 2011, 29, 8279-8284.	1.7	195
8	Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics, 2017, 139, .	1.0	187
9	Evaluation of the Association of Maternal Pertussis Vaccination With Obstetric Events and Birth Outcomes. JAMA - Journal of the American Medical Association, 2014, 312, 1897.	3.8	177
10	The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine, 2014, 32, 5390-5398.	1.7	175
11	Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers. Pediatrics, 2013, 131, e1716-e1722.	1.0	163
12	Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016. Clinical Infectious Diseases, 2019, 68, 1444-1453.	2.9	126
13	Waning Tdap Effectiveness in Adolescents. Pediatrics, 2016, 137, e20153326.	1.0	111
14	Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project. Pediatrics, 2011, 127, S54-S64.	1.0	110
15	Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine, 2010, 28, 1062-1068.	1.7	108
16	Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. JAMA Pediatrics, 2012, 166, 1140.	3.6	104
17	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatric Infectious Disease Journal, 2015, 34, 983-991.	1.1	103
18	Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007–2013. Vaccine, 2016, 34, 968-973.	1.7	100

#	Article	IF	CITATIONS
19	Lack of Association of Guillain-Barre Syndrome With Vaccinations. Clinical Infectious Diseases, 2013, 57, 197-204.	2.9	96
20	Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA - Journal of the American Medical Association, 2015, 314, 1581.	3.8	91
21	Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstetrics and Gynecology, 2015, 126, 1069-1074.	1.2	86
22	Attitudes and Beliefs of Parents Concerned About Vaccines: Impact of Timing of Immunization Information. Pediatrics, 2011, 127, S120-S126.	1.0	79
23	Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine, 2017, 35, 5314-5322.	1.7	79
24	Intraseason Waning of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2019, 68, 1623-1630.	2.9	75
25	Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. American Journal of Epidemiology, 2018, 187, 161-169.	1.6	70
26	Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ, The, 2013, 347, f4249-f4249.	3.0	68
27	Risk Factors for Developing Apnea After Immunization in the Neonatal Intensive Care Unit. Pediatrics, 2008, 121, 463-469.	1.0	66
28	Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children. JAMA Pediatrics, 2013, 167, 1111.	3.3	65
29	Algorithm to assess causality after individual adverse events following immunizations. Vaccine, 2012, 30, 5791-5798.	1.7	61
30	Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status. Pediatrics, $2019,143,.$	1.0	60
31	Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics, 2016, 138, .	1.0	59
32	Licensed pertussis vaccines in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 2684-2690.	1.4	57
33	Lack of Association Between Acellular Pertussis Vaccine and Seizures in Early Childhood. Pediatrics, 2010, 126, 263-269.	1.0	55
34	Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants. Pediatric Infectious Disease Journal, 2012, 31, 64-71.	1.1	55
35	Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine, 2010, 28, 7865-7872.	1.7	54
36	Immunization and Bell's Palsy in Children: A Case-Centered Analysis. American Journal of Epidemiology, 2012, 175, 878-885.	1.6	49

#	Article	IF	CITATIONS
37	Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine, 2012, 31, 271-277.	1.7	46
38	Recurrent Guillain-Barre Syndrome Following Vaccination. Clinical Infectious Diseases, 2012, 54, 800-804.	2.9	45
39	Timely Versus Delayed Early Childhood Vaccination and Seizures. Pediatrics, 2014, 133, e1492-e1499.	1.0	45
40	Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years. Pediatrics, 2012, 129, 809-814.	1.0	44
41	Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine, 2017, 35, 3395-3400.	1.7	44
42	Epidemiologic and Clinical Features of Bell's Palsy among Children in Northern California. Neuroepidemiology, 2012, 38, 252-258.	1.1	43
43	First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. Journal of Pediatrics, 2017, 187, 234-239.e4.	0.9	42
44	Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine, 2011, 29, 6592-6597.	1.7	41
45	Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics, 2018, 141, e20173310.	1.0	41
46	Understanding the Role of Human Variation in Vaccine Adverse Events: The Clinical Immunization Safety Assessment Network. Pediatrics, 2011, 127, S65-S73.	1.0	40
47	Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Journal of Epidemiology, 2013, 177, 131-141.	1.6	39
48	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012–13, 2013–14, and 2014–15. Vaccine, 2019, 37, 6673-6681.	1.7	39
49	Evaluation of Immunization Rates and Safety Among Children With Inborn Errors of Metabolism. Pediatrics, 2011, 127, e1139-e1146.	1.0	38
50	Safety of Measles-Containing Vaccines in 1-Year-Old Children. Pediatrics, 2015, 135, e321-e329.	1.0	38
51	Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics, 2019, 144, e20183466.	1.0	38
52	Safety of Trivalent Inactivated Influenza Vaccine in Children Aged 24 to 59 Months in the Vaccine Safety Datalink. JAMA Pediatrics, 2011, 165, 749.	3.6	37
53	One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children. Pediatric Infectious Disease Journal, 2013, 32, 760-767.	1.1	36
54	Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP–IPV) vaccine. Vaccine, 2014, 32, 3019-3024.	1.7	36

#	Article	IF	CITATIONS
55	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine, 2021, 39, 5428-5435.	1.7	36
56	Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS ONE, 2020, 15, e0229279.	1,1	34
57	Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization. Pediatric Infectious Disease Journal, 2010, 29, 613-617.	1.1	33
58	Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine, 2012, 30, 3929-3936.	1.7	32
59	Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009. Vaccine, 2011, 29, 6920-6927.	1.7	31
60	Influenza Vaccination During Pregnancy. American Journal of Preventive Medicine, 2016, 50, 480-488.	1.6	31
61	A Role for Genetics in the Immune Response to the Varicella Vaccine. Pediatric Infectious Disease Journal, 2007, 26, 300-305.	1.1	30
62	Suddenâ€Onset Sensorineural Hearing Loss after Immunization. Otolaryngology - Head and Neck Surgery, 2016, 155, 81-86.	1.1	30
63	A framework for research on vaccine effectiveness. Vaccine, 2018, 36, 7286-7293.	1.7	30
64	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	1.0	30
65	Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. Obstetrics and Gynecology, 2018, 132, 35-44.	1.2	27
66	Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2020, 70, 1484-1486.	2.9	26
67	Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age. Pediatric Infectious Disease Journal, 2012, 31, e133-e140.	1.1	23
68	Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine, 2016, 34, 4172-4179.	1.7	23
69	Preterm Infants' T Cell Responses to Inactivated Poliovirus Vaccine. Journal of Infectious Diseases, 2010, 201, 214-222.	1.9	22
70	Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine, 2019, 37, 5422-5427.	1.7	22
71	Differential maternal responses to a newly developed vaccine information pamphlet. Vaccine, 2009, 28, 323-328.	1.7	21
72	Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. Vaccine, 2019, 37, 195-201.	1.7	20

#	Article	IF	CITATIONS
73	Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110212.	1.0	20
74	Populationâ€based assessment of risks for severe COVIDâ€19 disease outcomes. Influenza and Other Respiratory Viruses, 2022, 16, 159-165.	1.5	20
75	Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4–6 Years of Age. Pediatric Infectious Disease Journal, 2008, 27, 341-346.	1.1	19
76	Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. Pediatric Neurology, 2017, 76, 72-78.	1.0	19
77	Incidence of Genital Warts in Adolescents and Young Adults in an Integrated Health Care Delivery System in the United States Before Human Papillomavirus Vaccine Recommendations. Sexually Transmitted Diseases, 2013, 40, 534-538.	0.8	18
78	Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011. Vaccine, 2016, 34, 167-171.	1.7	18
79	Exploring California's new law eliminating personal belief exemptions to childhood vaccines and vaccine decision-making among homeschooling mothers in California. Vaccine, 2019, 37, 742-750.	1.7	18
80	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. Journal of Immunology, 2020, 205, 877-882.	0.4	17
81	An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine, 2012, 30, 4585-4587.	1.7	16
82	Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatric Infectious Disease Journal, 2016, 35, 662-672.	1.1	16
83	Recurrent sterile abscesses following aluminium adjuvant-containing vaccines. BMJ Case Reports, 2009, 2009, bcr0920080951-bcr0920080951.	0.2	16
84	Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine, 2017, 35, 2668-2675.	1.7	15
85	Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. Vaccine, 2017, 35, 1873-1878.	1.7	15
86	Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink. Vaccine, 2017, 35, 5872-5877.	1.7	15
87	Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and <i>Haemophilus influenzae</i> type b vaccine: a randomized trial in the United States. Human Vaccines and Immunotherapeutics, 2019, 15, 809-821.	1.4	15
88	Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016–17 season. Vaccine, 2020, 38, 2202-2208.	1.7	14
89	An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP–IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine, 2012, 30, 668-674.	1.7	13
90	Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine, 2018, 36, 2356-2363.	1.7	11

#	Article	IF	CITATIONS
91	Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. Academic Pediatrics, 2018, 18, 754-762.	1.0	11
92	Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010–2016. Journal of Infectious Diseases, 2020, 221, 1703-1712.	1.9	11
93	Kinrix™: a new combination DTaP–IPV vaccine for children aged 4–6 years. Expert Review of Vaccines, 2008, 7, 1309-1320.	2.0	10
94	Long term risk of developing type 1 diabetes after HPV vaccination in males and females. Vaccine, 2019, 37, 1938-1944.	1.7	10
95	Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 194-201.	0.6	10
96	Shouting at each other into the void: A linguistic network analysis of vaccine hesitance and support in online discourse regarding California law SB277. Social Science and Medicine, 2020, 266, 113216.	1.8	10
97	Parental vaccine attitudes, beliefs, and practices: initial evidence in California after a vaccine policy change. Human Vaccines and Immunotherapeutics, 2021, 17, 1675-1680.	1.4	10
98	Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. JMIR Research Protocols, 2019, 8, e11333.	0.5	10
99	Comprehensive Assessment of Serious Adverse Events Following Immunization by Health Care Providers. Journal of Pediatrics, 2013, 162, 1276-1281.e1.	0.9	9
100	Risk factors and familial clustering for fever $7\hat{a} \in 10$ days after the first dose of measles vaccines. Vaccine, 2017, 35, 1615-1621.	1.7	9
101	Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy. American Journal of Epidemiology, 2020, 189, 1379-1388.	1.6	9
102	Temporal Trends in Undervaccination: A Population-Based Cohort Study. American Journal of Preventive Medicine, 2021, 61, 64-72.	1.6	9
103	Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study. Vaccine, 2012, 30, 3360-3368.	1.7	8
104	Use of acellular pertussis vaccines in the United States: can we do better?. Expert Review of Vaccines, 2017, 16, 1175-1179.	2.0	8
105	The safety of live attenuated influenza vaccine in children and adolescents 2 through 17Âyears of age: A Vaccine Safety Datalink study. Pharmacoepidemiology and Drug Safety, 2018, 27, 59-68.	0.9	8
106	Adults hospitalized with breakthrough COVIDâ€19 have lower mortality than matched unvaccinated adults. Journal of Internal Medicine, 2022, 292, 377-384.	2.7	8
107	Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 412-419.	1.4	7
108	Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Pharmacoepidemiology and Drug Safety, 2018, 27, 921-925.	0.9	7

#	Article	IF	CITATIONS
109	Homeschooling parents in California: Attitudes, beliefs and behaviors associated with child's vaccination status. Vaccine, 2020, 38, 1899-1905.	1.7	7
110	Comment on "The impact of past vaccination coverage and immunity on pertussis resurgenceâ€. Science Translational Medicine, 2018, 10, .	5.8	6
111	Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine, 2019, 37, 76-79.	1.7	6
112	Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine, 2021, 39, 3614-3620.	1.7	5
113	Assessment of Exemptions From Vaccination in California, 2015 to 2027. Annals of Internal Medicine, 2020, 172, 362.	2.0	5
114	Genetic associations with a fever after measles-containing vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 1763-1769.	1.4	5
115	Long-term Immune Responses to Pneumococcal Conjugate Vaccines in Children Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 990-997.	1.1	4
116	Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine, 2019, 37, 3296-3302.	1.7	4
117	If Influenza Vaccines Wane, Can We Delay Vaccination Without Compromising Coverage?. Clinical Infectious Diseases, 2020, 70, 1560-1561.	2.9	4
118	Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Diphtheria-tetanus-acellular Pertussis and Haemophilus influenzae Type B Vaccines in Children 15 Months of Age. Pediatric Infectious Disease Journal, 2011, 30, e164-e169.	1.1	3
119	Vaccine safety in special populations. Hum Vaccin, 2011, 7, 269-271.	2.4	3
120	Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine, 2019, 37, 4460-4467.	1.7	3
121	Immunogenicity and safety of the <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized. multicenter study in infants. Human Vaccines and Immunotherapeutics. 2019, 15, 327-338.	1.4	3
122	Parental risk factors for fever in their children 7–10 days after the first dose of measles-containing vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 875-880.	1.4	3
123	Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study. Open Forum Infectious Diseases, 2020, 7, ofaa179.	0.4	3
124	A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010–2016. Vaccine, 2021, , .	1.7	3
125	Developing the next generation of vaccinologists. Vaccine, 2011, 29, 9296-9297.	1.7	2
126	Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine, 2017, 35, 3564-3574.	1.7	2

#	Article	IF	CITATIONS
127	Patterns of childhood immunization and all-cause mortality. Vaccine, 2017, 35, 6643-6648.	1.7	2
128	Reply to Skowronski, De Serres, and Orenstein. Clinical Infectious Diseases, 2019, 69, 1085-1086.	2.9	2
129	Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine) Tj ETQq1 1 0.784314 rgE 3, randomized trial. Vaccine, 2021, 39, 1534-1543.	3T /Overlo 1.7	ck 10 Tf 50 2
130	School-level perceptions and enforcement of the elimination of nonmedical exemptions to vaccination in California. Human Vaccines and Immunotherapeutics, 2021, 17, 1986-1993.	1.4	2
131	Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine, 2022, 40, 2568-2573.	1.7	2
132	Differentiating Sepsis From Adverse Events After Immunization in the Neonatal Intensive Care Unit. JAMA Pediatrics, 2015, 169, 718.	3.3	1
133	Electronic Medical Record Intervention to Improve Adherence to Prenatal Vaccination Recommendation [12F]. Obstetrics and Gynecology, 2019, 133, 65S-65S.	1.2	1
134	Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. Human Vaccines and Immunotherapeutics, 2020, 16, 3098-3102.	1.4	1
135	Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children. Human Vaccines and Immunotherapeutics, 2020, 16, 1753-1761.	1.4	1
136	Factors that may explain observed associations between trivalent influenza vaccination and gastrointestinal illness in young children. Vaccine, 2013, 31, 3894-3898.	1.7	0
137	Kaiser Permanente Vaccine Study Center: Highlights of 2009–2012. Vaccines, 2013, 1, 139-153.	2.1	O
138	Studying attitudes towards vaccine hesitance and California law SB 277 in online discourse: A dataset and methodology. Data in Brief, 2021, 35, 106841.	0.5	0
139	Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. Expert Review of Vaccines, 2022, 21, 899-907.	2.0	O
140	Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Vaccine, 2022, 40, 774-779.	1.7	0